Livzon Pharmaceutical Group

Livzon Pharmaceutical Group OCF Margin

The Operating Cash Flow Margin of Livzon Pharmaceutical Group (000513.SZ) as of Nov 2, 2026 is 26.69 %. In the previous year, Operating Cash Flow Margin was 25.22 % — a change of 5.85% (higher).

OCF Margin

26.69 %

YoY

5.85%

Last updated:

Operating Cash Flow Margin of Livzon Pharmaceutical Group is 2025 26.69 % . Operating Cash Flow Margin of Livzon Pharmaceutical Group was 2024 25.22 % . It decreases by 5.85% higher compared to the previous year.

The Livzon Pharmaceutical Group OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
14.31 CNY
Jan 1, 2019
18.83 CNY
Jan 1, 2020
20.54 CNY
Jan 1, 2021
15.77 CNY
Jan 1, 2022
21.95 CNY
Jan 1, 2023
26.14 CNY
Jan 1, 2024
25.22 CNY
Jan 1, 2025
26.69 CNY
The Livzon Pharmaceutical Group OCF Margin history
YEAROCF MarginYoY
26.69 %+5.85%
25.22 %-3.52%
26.14 %+19.06%
21.95 %+39.22%
15.77 %-23.22%
20.54 %+9.07%
18.83 %+31.62%
14.31 %-7.25%
15.42 %-7.74%
16.72 %+19.30%
14.01 %+8.30%
12.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Livzon Pharmaceutical Group Stock analysis

What does Livzon Pharmaceutical Group do? Livzon Pharmaceutical Group Inc is a large Chinese company specializing in the development and marketing of pharmaceutical products. It was founded in 1985 and is headquartered in Zhuhai, a city in the southern Chinese province of Guangdong. Livzon is now one of the largest companies in the Chinese pharmaceutical industry and also has a good international reputation. Business model and divisions: The company's business model is diverse and includes research and development, production and distribution of bio-pharmaceuticals, active pharmaceutical ingredients (APIs), generics, traditional Chinese medicines, and diagnostics. Livzon is divided into various divisions, including the bio-pharmaceutical division, the generics division, and the traditional Chinese medicine division. These divisions have different focuses and products. Bio-pharmaceuticals: The bio-pharmaceutical division focuses on the research and development of biopharmaceutical products based on biological processes. The goal is to develop new treatment options for serious diseases such as cancer, autoimmune diseases, or infectious diseases. The most well-known products include the cancer drug Lyophilized Powder Injection and the treatment for autoimmune diseases Levamisole Hydrochloride. Generics: In the generics division, Livzon produces patent-free drugs that offer an alternative to expensive original medications. The company places special emphasis on testing and certifying the quality of its products. Livzon has an extensive range of generics with active ingredients for various diseases, such as hypertension, diabetes, and gastrointestinal diseases. Traditional Chinese medicine: Livzon is one of the few modern pharmaceutical companies specializing in the development and marketing of traditional Chinese medicines. Plant extracts and components derived from animal products are used for therapeutic purposes. The most well-known products include Yiganerjing Cream, a remedy for eczema, and Huoluo Oil, used for joint pain. Products: Livzon has introduced a variety of products to the market in recent years that have gained international recognition. Particularly notable are the products in the bio-pharmaceutical division, which are used in cancer therapy. Additionally, generics and traditional Chinese medicines are important components of the product portfolio. As one of the leading companies in the Chinese pharmaceutical industry, Livzon strives to meet the needs of its customers and continuously expand its offerings. Furthermore, the company is investing heavily in expanding its research and development department to develop innovative products that better meet the needs of patients. Livzon Pharmaceutical Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Livzon Pharmaceutical Group stock

Operating Cash Flow Margin of Livzon Pharmaceutical Group is 26.69 % in 2025.

Operating Cash Flow Margin of Livzon Pharmaceutical Group changed from 25.22 % to 26.69 %, representing a 5.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Livzon Pharmaceutical Group since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Livzon Pharmaceutical Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Livzon Pharmaceutical Group

All Key Metrics — Livzon Pharmaceutical Group